Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases.
Founded by physician-scientists 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including asthma, pain, cancer and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human genetics sequencing efforts in the world and rapid response technologies being used for global good.
Basking Ridge (Clinical Operations & Biostats)
110 Allen Road
Basking Ridge, NJ 07920
Industrial Operations and Product Supply
81 Columbia Turnpike
Rensselaer, NY 12144
777 articles with Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. Announces Participation In Panel Discussions At RBC Capital Markets Conference
Regeneron Pharmaceuticals, Inc. Announces Presentation At Rodman & Renshaw 8TH Annual Healthcare Conference
Bayer HealthCare AG And Regeneron Pharmaceuticals, Inc. To Collaborate On VEGF Trap For The Treatment Of Eye Diseases; Regeneron Retains U.S. Commercialization Rights, Receives $75 Million Upfront, And Eligible For Up To $245 Million Of Milestone Payments
Regeneron Pharmaceuticals, Inc. Names Peter Powchik, M.D., Senior Vice President Of Clinical Development
Regeneron Pharmaceuticals, Inc. Announces Presentation At UBS Warburg Global Life Sciences Conference
National Institutes of Health (NIH) Selects Regeneron Pharmaceuticals, Inc. For Knockout Mouse Project; Regeneron Pharmaceuticals, Inc. Will Use Its VelociGene(R) Technology To Target 3,500 Genes Over Five Years, Providing New Models Of Human Diseases
Regeneron Pharmaceuticals, Inc. Reports Second Quarter Financial And Operating Results; BLA Filing For Auto-Inflammatory Diseases Planned For Early 2007; Two Antibody Candidates From VelocImmune(R) Program To Enter Clinical Trials Each Year Beginning In 2
Regeneron Pharmaceuticals, Inc. Receives Fast-Track Designation For The IL-1 Trap In CIAS1-Associated Periodic Syndromes (CAPS)
Regeneron Pharmaceuticals, Inc. Reports Positive Phase 1 Data For The VEGF Trap In Age-Related Macular Degeneration
Sanofi-Aventis (France) And Regeneron Pharmaceuticals, Inc. Expand Their VEGF Trap Oncology Collaboration To Japan; Regeneron To Receive $25 Million